Achieving a production growth to 3,250 cubic meters of reaction capacity—one of the highest globally in the sector—while also expanding the product portfolio to include additional therapies in high socio-health value areas.

Olon has outlined its development and consolidation strategy in the API market, driven by the recent acquisition of HuvePharma Italia and the production site in Garessio, Italy. With a strong presence in the market, offering 200 generic APIs and managing over 450 Drug Master Files worldwide, Olon is now expanding into the antispasmodic and antimalarial segments. This expansion leverages its established expertise in regulatory compliance, advanced technologies, and quality standards, ensuring excellence across its growing product portfolio

The recently acquired manufacturing plant brings extensive expertise in API development and production, complemented by a strong track record in adopting and integrating cutting-edge technologies. With its production lines fully automated, the facility has advanced the production of a critical antimalarial treatment, semi-synthetic artemisinin, using innovative photo-oxidation technology and nanoparticle manufacturing.

This work addresses a critical global health challenge: the volatile vegetal artemisinin market, which has faced price shocks since the mid-2000s. These fluctuations create uncertainty for ACT manufacturers, jeopardizing the affordability and availability of lifesaving therapies for malaria patients, particularly vulnerable children under five. Additionally, the traditional artemisinin supply chain remains fragile, subject to weather- and climate-related risks.

By ensuring a stable and resilient supply chain for artemisinin, the plant plays a pivotal role in safeguarding access to affordable ACTs, which save millions of lives annually. This dedication underscores the commitment to delivering life-saving therapies to those who need them most.